Scholarlink

<p>Interstitial lung diseases (ILDs) are characterized by progressive lung scarring. Fibroblast activation protein (FAP), overexpressed on activated fibroblasts, has emerged as a key molecular target for imaging active fibrosis. This systematic review synthesizes the current evidence on the role of FAP-targeted imaging in evaluating ILD. A systematic search was conducted across PubMed, Scopus, and Web of Science according to PRISMA guidelines. Twelve studies met the inclusion criteria and were included in a qualitative synthesis. FAP inhibitors (FAPI) imaging consistently demonstrated elevated tracer uptake in ILD patients, showing strong spatial correlation with fibrotic patterns on high-resolution computed tomography (HRCT), particularly reticulation. Increased FAPI uptake was significantly associated with declining lung function, including forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO). Histopathological analyses confirmed that FAPI uptake corresponds to fibroblast-rich regions, validating its specificity for active fibrogenesis. Dual-tracer imaging showed potential in differentiating fibrotic from inflammatory activity. FAP-targeted imaging is a promising non-invasive modality for visualizing and quantifying active fibrosis in ILD. It offers valuable insights into disease activity, functional impairment, and prognosis, potentially guiding personalized treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fibroblast activation protein-targeted molecular imaging in interstitial lung disease: a systematic review

  • 期刊论文

  • 发表日期：

    2026年5月7日

查看全文
  • Ali Ghorbani Olya,
  • Mehrzad Bahtouee,
  • Esmail Jafari,
  • Maryam Ravanipour,
  • Ali Hamidi,
  • Nahid Aram,
  • Soodabeh Zendeboodi,
  • Moloud Abbaszadeh,
  • Majid Assadi

摘要

Interstitial lung diseases (ILDs) are characterized by progressive lung scarring. Fibroblast activation protein (FAP), overexpressed on activated fibroblasts, has emerged as a key molecular target for imaging active fibrosis. This systematic review synthesizes the current evidence on the role of FAP-targeted imaging in evaluating ILD. A systematic search was conducted across PubMed, Scopus, and Web of Science according to PRISMA guidelines. Twelve studies met the inclusion criteria and were included in a qualitative synthesis. FAP inhibitors (FAPI) imaging consistently demonstrated elevated tracer uptake in ILD patients, showing strong spatial correlation with fibrotic patterns on high-resolution computed tomography (HRCT), particularly reticulation. Increased FAPI uptake was significantly associated with declining lung function, including forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO). Histopathological analyses confirmed that FAPI uptake corresponds to fibroblast-rich regions, validating its specificity for active fibrogenesis. Dual-tracer imaging showed potential in differentiating fibrotic from inflammatory activity. FAP-targeted imaging is a promising non-invasive modality for visualizing and quantifying active fibrosis in ILD. It offers valuable insights into disease activity, functional impairment, and prognosis, potentially guiding personalized treatment strategies.